Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9868 | 0.76 | AKT1 (0.46) | AKT1AKT2 | |
| SCHEMBL6741233 | 0.74 | AKT1 (0.45) | AKT1AKT2 | |
| SCHEMBL28531472 | 0.74 | AKT1 (0.45) | AKT1AKT2 | |
| SCHEMBL1646236 | 0.74 | GP6 (0.37) | AKT1AKT2 | |
| SCHEMBL13078874 | 0.73 | METAP2 (0.32) | AKT1AKT2 | |
| SCHEMBL12989702 | 0.72 | AKT1 (0.48) | AKT1AKT2 | |
| SCHEMBL294336 | 0.72 | AKT2 (0.59) | AKT1AKT2 | |
| SCHEMBL297000 | 0.72 | IDO1 (0.31) | — | |
| Chloromethane SCHEMBL27566997 | 0.71 | AKT1 (0.42) | AKT1AKT2 | |
| SCHEMBL27586213 | 0.71 | AKT1 (0.42) | AKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242970-B2 | Lactam derivatives useful as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-01-26 | — | — | US | claimed |
| EP-2638008-B1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-07-01 | — | — | EP | claimed |
| CN-102471291-B | 3-triazolylphenyl-substituted sulfide derivatives for use as acaricides and insecticides | BAYER CROPSCIENCE AG | 2015-04-22 | — | — | CN | claimed |
| EP-2638008-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-09-18 | — | — | EP | claimed |
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-12 | — | — | US | claimed |
| CN-103228643-A | Benzazole derivatives as histamine H4 receptor ligands | BIOPROJET SOC CIV | 2013-07-31 | — | — | CN | claimed |
| CN-103201261-A | Lactam derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD | 2013-07-10 | — | — | CN | claimed |
| CN-102471291-A | 3-triazolylphenyl-substituted sulfide derivatives for use as acaricides and insecticides | BAYER CROPSCIENCE AG | 2012-05-23 | — | — | CN | claimed |
| WO-2012063207-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-05-18 | — | — | WO | claimed |
| CN-101137623-A | N-sulphonylpyrroles and their use as histone deacetylase inhibitors | NYCOMED GMBH (DE) | 2008-03-05 | — | — | CN | claimed |
| US-20230201161-A1 | Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment | 4SC AG (DE) | 2023-06-29 | — | — | US | disclosed |
| EP-3941924-A1 | TECHNOLOGIES USEFUL FOR OLIGONUCLEOTIDE PREPARATION | Wave Life Sciences Ltd. (SG) | 2022-01-26 | — | — | EP | disclosed |
| US-20210145799-A1 | PHARMACEUTICAL COMBINATION PRODUCTS COMPRISING A HISTONE DEACETYLASE (HDAC) INHIBITOR AND A TLR7 AGONIST AND/OR TLR8 AGONIST FOR THE TREATMENT OF CANCER | 4SC AG (DE) | 2021-05-20 | — | — | US | disclosed |
| US-20210113528-A1 | Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy | 4SC AG (DE) | 2021-04-22 | — | — | US | disclosed |
| WO-2021064188-A1 | COMBINATION COMPRISING HDAC INHIBITOR, CTLA-4 INHIBITOR AND A PD-1 INHIBITOR OR PD-L1 INHIBITOR FOR CANCER TREATMENT | 4SC AG (DE) | 2021-04-08 | — | — | WO | disclosed |
| US-7132438-B2 | Benzimidazole derivatives | AMGEN INC. (US) | 2006-11-07 | — | — | US | disclosed |
| WO-2006097474-A1 | N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | NYCOMED GMBH (DE) | 2006-09-21 | — | — | WO | disclosed |
| EP-1434579-A1 | IMIDAZOLE DERIVATIVES AS ANTIINFLAMMATORY AGENTS | Tularik Inc. (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20030144286-A1 | Benzimidazole derivatives | TULARIK, INC | 2003-07-31 | — | — | US | disclosed |
| WO-2003030902-A1 | IMIDAZOLE DERIVATES AS ANTI-INFLAMMATORY AGENTS | TULARIK INC. (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210145799-A1 | PHARMACEUTICAL COMBINATION PRODUCTS COMPRISING A HISTONE DEACETYLASE (HDAC) INHIBITOR AND A TLR7 AGONIST AND/OR TLR8 AGONIST FOR THE TREATMENT OF CANCER | HDAC8, TLR8, TLR7 | AKT1 2686/4885AKT2 2940/4885 |
| US-20210113528-A1 | Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy | HDAC7, HDAC1, HDAC11 | AKT1 2131/4885AKT2 2385/4885 |
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | AKT1 643/4885AKT2 584/4885 |
| US-20030144286-A1 | Benzimidazole derivatives | NFATC1, STAT1, IRF3 | AKT1 2154/4885AKT2 1276/4885 |
| US-20230201161-A1 | Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment | HDAC1, HDAC3, HDAC11 | AKT1 1965/4885AKT2 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.